|
|
|
|
| |||||
Lamisil
WARNINOS Overdosage may occur at 2 mg, four times the maximum recommended therapeutic dose 0.5 mg ; . Patients should be cautioned not to exceed prescribed dosage. Because of its depressant CNS effects, patients should be cautioned against engaging in hazardous occupations requinng complete mental alertness and also about the simultaneous ingestion of alcohol and other CNS depressant drugs. Anterograde amnesia arid paradoxical reactions have been reported with HALCION and some.
Tier 3 Drug ACIPHEX Suggested Alternative s ; omeprazole PROTONIX Prilosec OTC not covered, but available for -25 for a 30-day supply. ; PREMPRO, FEMHRT FLOVENT, or FLOVENT + SEREVENT Nonprescription generic loratadine not covered, but available in stores for -20 for a 30-day supply. ; glyburide, glipizide MICARDIS, AVAPRO ALESSE ibuprofen, naproxen, sulindac, diclofenac amoxicillin, cephalexin, cefuroxime ibuprofen, naproxen, sulindac, diclofenac PREMARIN Nonprescription ALAVERT or generic loratadine not covered, but available in stores for -20 for a 30-day supply. ; verapamil long-acting ibuprofen, naproxen, indomethacin, piroxicam, sulindac ORTHO-CEPT RETIN-A MICARDIS. AVAPRO DETROL LA oxybutinin lovastatin LIPITOR or PRAVACHOL AVELOX, TEQUIN ibuprofen, naproxen, sulindac, diclofenac FLONASE, RHINOCORT omeprazole PROTONIX Prilosec OTC not covered, but available in stores for -25 for a 30 day supply. ; FEMHRT, PREMPRO morphine sulfate long-acting MS-CONTIN nifedipine long-acting NORVASC Omeprazole PROTONIX Prilosec OTC not covered, but available in stores for -25 for a 30 day supply. ; ELIDEL carisoprodol, cyclobenzaprine, methocarbamol LAMISIL NORVASC nifedipine long-acting cefuroxime dlitiazem long-acting ibuprofen, naproxen, sulindac, diclofenac Acetaminophen + tramadol clobetasol, betamethasone dipropionate augmented PREMARIN VAGINAL CREAM, ESTRING cefuroxime enalapril, lisinopril, fosinopril, quinapril hydrocodone + acetaminophen ibuprofen, naproxen, sulindac, diclofenac lovastatin LIPITOR or PRAVACHOL AXERT, MAXALT, IMITREX Nonprescription ALAVERT or generic loratadine not covered, but available in stores for -20 for a 30-day supply. ; Tier1 x Tier2 x. 1. F. Gao et al., Nature 397, 436 1999 ; . 2. B. Hahn, G. M. Shaw, K. M. De Cock, P. M. Sharp, Science 287, 607 2000 ; . 3. M. Santiago et al., Science 295, 465 2002 ; . 4. B. Beer et al., J. Virol. 75, 12014 2001 ; . 5. V. Courgnaud et al., J. Virol. 76, 8298 2002 ; . 6. Materials and Methods are available as supporting online material on Science Online. 7. T. L. Goldberg, M. Ruvolo, Mol. Biol. Evol. 14, 976 1997 ; . 8. This work was supported by NIH grants RO1 AI44596, R01 AI50529, and N01 AI85338. Supporting Online Material sciencemag cgi content full 300 5626 1713 DC1 Materials and Methods Table S1 References. Lamisil tab 250 mg
A marketplace and pathology that Fogarty Engineering has been looking at for ten years. In that time, the outfit has moved various device concepts for the indication between front and back burners. Now, it's ready to get cooking. Published in The key driver of treatment in the obesity market is the growing understanding within the medical community and among individuals that excess weight is unhealthy, not just unsightly. Insurance companies are also beginning to recognize the problem and the merits of treating it, Fogarty says: "If you convert someone from hypertensive to non-hypertensive, from diabetic to not diabetic by weight reduction and dietary control, that person is healthier and less likely to require medical treatments that raise costs." Obese people are also at far greater risk of complication if they need to undergo surgery. Live Fitter, Satiety aims to develop two technology platforms, one of which comes out of Fogarty Research and another that hails from The Foundry, based in the Bay Area and founded by Alan Will and Look Better Hanson Gifford. The company is so young that the founders are not yet willing to say much about the devices or their application--only that the Foundry brings an endoscopic approach to treatment that October 2001 involves using a balloon to reduce stomach volume. Fogarty Research brings a laparoscopic approach that involves 1-centimeter incisions. Already it's clear that the three-month old company is looking beyond treating morbidly obese people weighing, say, 600 pounds, to the huge market populated by moderately obese people weighing in at 300 pounds or so. "If you go state by state, there is not a state in the union where 20% of the population isn't moderately obese, " Fogarty declares. Because obesity runs a spectrum of disease states, from moderate to morbidly obese, the technology appropriate for treating the different types of patients is not necessarily the same, Fogarty declares. Hence, the two platforms. "What you use depends on the patient's degree of obesity, " Fogarty says, though he concedes that it is possible that a device to treat a morbidly obese person DRUGS DOMINATE LI TYLE MARKETS "might also be harnessed to help someone with a Exhibit 3 less severe a problem who Product Manufacturer Launch Date Indication is looking for an assist with weight loss." Vaniqa BristolSept. 2000 Unwanted The regulatory routes eflornithine topical ; Myers Squibb facial hair could also be different for Sarafem fluoxetine ; Eli Lilly July 2000 Extreme PMS Satiety's two platforms, Fogarty notes, though he Lamiil terbinafine ; Novartis May 1999 Toenail fungus can't say for sure. The Caverject alprostadil ; Pharmacia Jan. 1999 Erectile disfunction firm has not yet talked to the FDA about its reasonSonata zaleplan ; Wyeth-Ayerst Sept. 1998 Insomnia ing. "But if you had someXenical orlistat ; Roche April 1998 Obesity body 30% over normal body weight who required Viagra sildenafil ; Pfizer April 1998 Erectile disfunction a semi-elective surgical Detrol tolterodine ; Pharmacia March 1998 Overactive bladder procedure, and if you had a method--possibly a Meridia sibutramine ; Knoll .eb. 1998 Obesity temporary one--by which you could effect weight Propecia finasteride ; Merck Jan. 1998 Male pattern baldness reduction and so reduce Ditropan oxybutynin ; Alza Dec. 1997 Overactive bladder that person's risk of complications.that Zyban bupropion ; Glaxo Wellcome July 1997 Smoking cessation might be very beneficial." Fogarty says that Satiety SOURCE: Industry sources and company reports is doing animal studies now, and will certainly consult with the FDA on a clinical trial design. Demonstrating safety shouldn't be too onerous a task, he figures: less invasive devices are, almost by definition, safer than what's gone before. People have tried device approaches to treating obesity previously--putting objects in the stomach to take up space--but complications arose with migration of the device. Fogarty says Satiety has figured out a way to avoid the problem, by suturing or stapling a volume-displacement device in place. Satiety's approach is also less invasive, he notes, and that too should increase the safety of the procedure. Satiety will be coming into the obesity market against gastric bypass surgery, which surgically sections off part of the stomach to reduce its holding capacity. Fogarty notes that patients need to have a certain percentage of body mass over the norm in order to get approval to undergo that very invasive surgical procedure and be reimbursed for it through insurance. There are a few centers that can do it laparoscopically, "but only a very few, because it's very technologically challenging, " Fogarty explains. He says Satiety intends to make stomach volume-reduction easier for physicians and safer for patients. Those factors promise to make the procedure a viable option for more people than ever before--as do Satiety's plans to put its tool into new hands. Currently, only surgeons perform gastric bypass surgery, but general internists who presently use endoscopy in a windhover.
IBS irritable bowel syndrome. Source: Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial. Lancet 2000; 355: 1035-1040. Reprinted with permission and lotrisone.
NAH.098 30.000: Number of brothers 50 when diagnosed w other kind of cancer FHBAGE30 Frequency Percent None 35 14.34 01-20 brothers 38 15.57 21 + 0.00 97 Refused 2 0.82 98 Not ascertained 0 0.00 99 Don't know 169 69.26 Frequency Missing 31184. Objective: To determine the efficacy of Bixa Orellana BO ; in patients with benign prostatic hyperplasia BPH ; presenting moderate lower urinary tract symptoms LUTS ; . Materials and Methods: It is a prospective double-blind randomized placebo-controlled study. One thousand four hundred and seventy eight patients presenting moderate LUTS associated to BPH were interviewed, from whom we selected 136 to fulfill the criteria of inclusion and exclusion. Assignation was performed at random in blocks of four to receive B0 at a dose of 250 mg 3 times a day or placebo Pbo ; for 12 months, 68 patients were assigned to each group. From the patients in the study we obtained data of demographic, epidemiologic, symptom score, uroflowmetry and post void residual urine variables. Results: Basically both groups were compared clinically, demographically and biochemically. Throughout the study variations of symptom score, mean delta symptom score during each visit and the final average delta were similar for both groups BO - 0.79 1.87 and Pbo - 1.07 1.49 ; p 0.33 ; . Similarly variations of Qmax mean, Qmax average delta and final average delta were similar BO 0.44 1.07 and Pbo 0.47 1.32 ; p 0.88 ; . Variations of post void residual urine mean, post void residual urine average delta in each visit and the final average delta were similar for both groups BO 4.24 11.69 and Pbo 9.01 18.66 ; p 0.07 ; . No differences were found in the answers of clinically significant improvement assessed with relative risk and risk differences, even though the proportion of adverse effects was similar for both groups. Conclusion: Patients with BPH that present moderate LUTS did not show any benefit receiving BO when compared to placebo. Key words: prostatic hyperplasia; bladder outlet obstruction; phytotherapy; Bixa orellana Int Braz J Urol. 2007; 33: 493-501. Staval LLC. is a Corporation registered in the state of New Jersey, with its primary office in Princeton, New Jersey. The Company was founded in 2007, solely for the purpose of developing, patenting and commercializing a family of target specific use healthcare related disinfectant products. The products are specifically and uniquely designed to eliminate fungi and other organisms which are present in footwear "shoes, insoles, boots and sneakers" regardless of material; collectively "footwear" ; and which constitute a major factor in the transmission of infections of the feet including Athlete's Foot "tinea pedis" ; and toenail fungus "onychomycosis" or "tinea unguium" ; . According to US Health and Nutrition Examination Survey NHANES 1 ; conducted by the US Health Department, 11% of the US population 32 million people ; have Athlete's Foot, with a subset of about 6.2 million having toenail fungal infections caused over time by persistent Athlete's Foot infection. There is a direct connection between Athlete's Foot infection and toenail fungus. Left untreated, even on a sub clinical level, Athlete's Foot infection may develop into toenail fungus. In recent years, substantial improvements have been made with medications such as Laimsil and Lotrimin ; intended to treat these infections on the foot. Even though these treatments improved our ability to manage these infections, the failure rate is unacceptably high. Moreover, recurrence rates with each of the various prescriptions "Rx" ; and over the counter "OTC" ; treatments are high. Consequently, the anti-fungal product category is one of the highest turnover categories in the market and pharmacy. The reason for the high failure and recurrence rates 52% to 77% ; is incomplete eradication of the fungus and or re-exposure to the fungus. Shoes from people with Athlete's Foot and onychomycosis are contaminated with the fungus that causes these diseases. Fungi are capable of surviving in shoes for long periods of time; months or even years. Patients can treat their disease with one of the existing topical or oral treatments and can wash their socks, but there are no effective methods available for treating the fungus within the footwear. Although the patient may complete a recommended course of topical and or oral antifungal treatment they have not addressed the persistent fungus in the shoes. Once the shoes are put back on, the patient is once again exposed to the fungus. Failure to eradicate the fungus in the shoes makes the existing medications for treating Athlete's Foot limited in their effectiveness. To achieve a complete cure and reduce the likelihood of recurrence necessitates the use of a complimentary antifungal product for the disinfection of the contaminated footwear to complete the treatment. Recognizing this need and the lack of any existing products, Staval was founded to develop, patent and commercialize such products. A provisional patent was filed in October of 2005 and testing for product development has been performed at the Center for Medical Mycology, University Hospitals of Cleveland. Testing in support of the Company's intellectual property was completed in April of 2006 and a comprehensive domestic and international patent application was filed in October of 2006. Additional testing will continue to assure product optimization, development and improvement over time and famvir. Paragraph and should include the full name of the granting agency and grant number. See instructions for Disclosure of Commercial Interests. Acknowledgment of individuabs should not exceed four typed lines. Drug company support of any kind must be acknowledged. Added to their diverse employee base with the addition of Deborah Ashton as the director of diversity and Lynn Bonner as the director of market outreach. Deborah Ashton has joined the human resources team and is responsible for managing Harley-Davidson's diversity and inclusion efforts. In her Ashton role, Ashton will foster a culture of ownership to integrate diversity and inclusion into all aspects of the company. Ashton's expertise in diversity and human resources comes from over 20 years of work experience. Most recently, she was president of New Explorations Unlimited, a company she formed that focused on executive coaching, leadership development, diversity and multiculturalism. She holds a bachelor's degree in psychology from Clarke College in Iowa and a doctorate in clinical psychology and public practice from Harvard University. She is a recipient of the Centurion of Diversity Award from the Hispanic Engineers & Information Technology and the U.S. Black Engineers & Information Technology. Lynn Bonner, director of market outreach within the customer relations and motorcycle product planning group, is responsible B o n for creating, promoting and implementing strategic close-to-the-customer programs for the company. Bonner is focused on ensuring Harley-Davidson's reach and relevance within the African American and Hispanic markets. Prior to joining Harley-Davidson, Bonner held a number of positions at Ford Motor Company on the Ford, Jaguar and Land Rover brands, including national pre-owned brand manager, cultural marketing manager, new dealer launch manager and neurontin. Check with Customer Service for Product Availability ; Sorted Alpha by Item Description Vendor Name IVAX PHAMACEUTICALS IVAX PHAMACEUTICALS AMIDE PHARMA UNITED RESEARCH LABS PRIME MARKETING, LLC SANOFI PASTEUR SANOFI PASTEUR SANOFI PASTEUR PROMETHEUS IVAX PHAMACEUTICALS BAXTER HLTHCARE MED DELIVERY BAXTER HLTHCARE MED DELIVERY BAXTER HLTHCARE MED DELIVERY MONARCH PHARMACEUTICALS MONARCH PHARMACEUTICALS JOHNSON & JOHNSON SLC JOHNSON & JOHNSON SLC ANDRX PHARMACEUTICAL MAYNE PHARMA MUTUAL PHARMACEUTICALS, CORP. MUTUAL PHARMACEUTICALS, CORP. MUTUAL PHARMACEUTICALS, CORP. MUTUAL PHARMACEUTICALS, CORP. MUTUAL PHARMACEUTICALS, CORP. MUTUAL PHARMACEUTICALS, CORP. NOVARTIS PHARM BOCA MEDICAL AMERICAN PHARM PARTNERS SCHWARZ PHARMA * MEDICIS PHARMACAL CORP MEDICIS PHARMACAL CORP AMERICAN PHARM PARTNERS GLOBAL PHARMACEUTICAL GLOBAL PHARMACEUTICAL GATE PHARMACEUTICALS MEDICIS PHARMACAL CORP MEDICIS PHARMACAL CORP MEDICIS PHARMACAL CORP WATSON PHARMA, INC. MARLOP PHARMACEUTICALS, INC. MARLOP PHARMACEUTICALS, INC. MARLEX PHARMACEUTICALS MARLYN NATURALLY ELAN PHARMACEUTICALS ELAN PHARMACEUTICALS ELAN PHARMACEUTICALS ELAN PHARMACEUTICALS ELAN PHARMACEUTICALS ELAN PHARMACEUTICALS NATURES'S VISION IVAX PHARMACEUTICALS BAXTER HEALTHCARE ASTRA ZENECA ASTRA ZENECA UCB MANUFACTURING INC SIRIUS LABORATORIES, INC. PUREPAC GLOBAL PHARMACEUTICAL AMERICAN PHARM PARTNERS AMERICAN PHARM PARTNERS DDN OBERGFEL, LLC DDN OBERGFEL, LLC DDN OBERGFEL, LLC HOPE PHARMACEUTICALS MAYNE PHARMA HOPE PHARMACEUTICALS MAYNE PHARMA UCB MANUFACTURING INC UCB MANUFACTURING INC H. D. Smith Item Number 672-2839 672-3993 104-8297 Item Description HYDROXYZN PAM 50mg IV 290960 HYDROXYZN PAM 50mg IV 290970 HYOSCYAMINE CAP .375mg 6302 HYOSCYAMINE SUBL .125 UR 6501 IBUPROFEN TABS 200mg HS 000201 IMOGAM RABIES 2ml 49281019020 IMOGAM RABIES 10ml 49281019010 IMOVAX RABIES 1ml 25010 IMURAN TABS 50mg 65483059010 INDAPAMIDE TAB 1.25mg IV 26260 INFUVITE ADULT MULTIVIT 2A9018 INFUVITE PEDI BLK 10DS 2A9061 INFUVITE PEDI MULTIVIT 2A9008 INTAL 112 METER SPRAY 79301108 INTAL 200 METER SPRAY 93001114 JOHNSONS BABY SHMP 15OZ 2N1 JOHNSONS BABY SHMP 15OZ LVNDR KETOPROFEN ER CP 200mg AN 2001 LABETALOL MDV 20ml 61703023322 LABETALOL TABS 100mg MU 035401 LABETALOL TABS 100mg MU 035405 LABETALOL TABS 200mg MU 035501 LABETALOL TABS 200mg MU 035505 LABETALOL TABS 300mg MU 035601 LABETALOL TABS 300mg MU 035605 LAMISIL SOL 1% 30ml 0078032882 LANCET ULTILET 28G BO 280001 LEUCOVRN DRY 500mg 63323071100 LEVSIN AMPS 1ml 000091153605 LIDEX CRM 60GM 99207051117 LIDEX OINT 60GM 99207051417 LIDOCN SDV 1% 2ml 63323020102 LIPRAM 10000 UNITS GB 4001 LIPRAM EC 4500 CAPS 703501 LOFIBRA CAP 200mg 57844032401 LOPROX SHAMPOO 240ml 207001020 LOPROX TOP SUSP 30ml 7002230 LOPROX TOP SUSP 60ml 7002260 LORAZEPAM INJ 2mg 1ml WL 6545 MARDROPS DX 30ml MR 043530 MARDROPS EX 30ml MR 043030 MARLEXATE POWDER 1 LB 14617 MARLYN FRMLA 50 60100 MAXIPIME 500mg VL 15ml 005310 MAXIPIME 1GM ADD 1479005420 MAXIPIME 1GM VL 15ml 479005430 MAXIPIME 2GM ADD 005510 MAXIPIME 2GM PB 51479005520 MAXIPIME 2GM VL 20ml 479005530 MELATONIN TAB 2TB 3mg ; MEMORY FORMULA TABS MEPERIDINE AMP 50mg ml 1ML5668 MERREM IV 500mg ADD 032515 MERREM IV 1GM ADD 310032115 METADATE ER TAB 20mg 014059407 METED SHAMPOO 4OZ 61004 METFORMIN TABS 500mg PP 65711 METHITEST CAP 10mg GB 3701 METHOTRX LPF 200mg 63323012108 METHOTRX LPF1000mg 63323012140 METHYLIN 2.5mg TB CHEW 13201 METHYLIN 5mg TB CHEW 13501 METHYLIN 10mg TB CHEW 13701 METHYLN BLU SDV 10ml 267050055 METHYLN BLU SDV 10ml 703040232 METHYLN BLU SDV 1ml 0267040044 METHYLN BLU SDV 1ml 1703040242 METHYLPHENDT TAB 5mg CE 53107 METHYLPHENDT TAB 10mg CE 53007 Pack Size 100 500 100 NDC UPC 00172290960 00172290970 52152016302 Fine Line 8510 May 2006. Serious side effects lamisilThe medicinal substances most frequently reported to the ADR register of the National Agency for Medicines during 2003 Medicinal substance levofloxacin Tavanic ; jopromide Ultravist ; celecoxib Celebra ; clozapine several products, e.g. Leponex, Froidir ; rofecoxib Vioxx, Vioxxakut ; simvastatin several products, e.g. Corolin, Lipcut, Zocor ; telithromycin Ketek ; ethoricoxib Arcoxia ; infliximab Remicade ; terbinafine Lqmisil ; atorvastatin Lipitor ; quetiapine Seroquel ; risperidone Risperdal ; ethinylestradiol + ethonogestrel Nuvaring vaginal ring ; ethinylestradiol + drospirenone Yasmin ; fluvastatin Canef, Lescol ; nitrofurantoin Nitrofur-C ; venlafaxine Efexor ; carbamazepine several products, e.g. Tegretol, Neurotol ; bupropion Zyban ; mirtazapine Remeron ; Number of reports 30 27 26. Medication mistakes account for an estimated .5 billion a year in extra medical costs from drugrelated injuries, according to the Institute of Medicine report. The Institute report said that confusion caused by drugs with similar names accounts for up to 25 percent of medication errors. Labeling and packaging mistakes caused 33 percent of errors. Also cited were mistakes made because pharmacists misread the handwriting of prescribing physicians. A 2003 Food and Drug Administration report noted one patient died "because 20 units of insulin was abbreviated as `20 U, ' but the `U' was mistaken for a zero." That same report revealed that another patient died after a physician ordered Taxol for a chemotherapy patient but the pharmacist prepared Taxotere, a different medication. The drugs Lamictal for epilepsy and Lamisil for nail infections are other examples of medications with similar names that have been found responsible for pharmacy errors, according to the FDA report. Those are the types of mistakes Dameron said he hopes can be avoided as pharmacies report their errors and the commission responds with statewide alerts. Dameron said adverse-event reports from pharmacies would include summaries of the incidents and suggested fixes. "Where did the system break down?" Dameron said. "Was it a staffing issue? Was it a distraction issue? Was it a sound-alike name?" Penalizing pharmacists for their mistakes won't ensure that future mistakes aren't made, Dameron said. "I want to assign responsibility to the environment in the pharmacy, " he said. "If I get rid of you because you made an error, the next guy is probably going to make the same error and acyclovir. To address capacity issues and create additional patient care space, Health Records will soon be moving! The physician's dictation workroom will be located in the area now designated as Materials Management office, down by the auditorium. This move should take place in July and notices will be posted. IV. Lack of Clinical Response for Sickle Cell Pain Indication and zovirax and Buy lamisil. Lamisil lotriminINFLUENZA AGENTS HMG-CoA REDUCTASE ANTIDEPRESSANTS ANTI-INFECTIVES amantadine INHIBITORS MISCELLANEOUS AGENTS ANTIBACTERIALS rimantadine pravastatin bupropion CEPHALOSPORINS TAMIFLU simvastatin bupropion ext-rel cefaclor LIPITOR mirtazapine cephalexin CARDIOVASCULAR NIACINS WELLBUTRIN XL OMNICEF ACE INHIBITORS NIASPAN SELECTIVE SEROTONIN ERYTHROMYCINS fosinopril REUPTAKE INHIBITORS SSRIs ; MACROLIDES BETA-BLOCKERS lisinopril citalopram azithromycin atenolol quinapril fluoxetine clarithromycin metoprolol ALTACE paroxetine erythromycins nadolol ACE INHIBITOR DIURETIC sertraline BIAXIN XL propranolol COMBINATIONS LEXAPRO FLUOROQUINOLONES COREG fosinopril-hydrochlorothiazide PAXIL CR ciprofloxacin tablet TOPROL-XL lisinopril-hydrochlorothiazide SEROTONIN NOREPINEPHRINE AVELOX CALCIUM CHANNEL quinapril-hydrochlorothiazide REUPTAKE INHIBITORS CIPRO SUSPENSION BLOCKERS ACE INHIBITOR CALCIUM SNRIs ; 3 CIPRO XR diltiazem ext-rel CYMBALTA CHANNEL BLOCKERS LEVAQUIN nifedipine ext-rel EFFEXOR LOTREL PENICILLINS verapamil ext-rel EFFEXOR XR amoxicillin TARKA NORVASC amoxicillin-clavulanate MIGRAINE ANGIOTENSIN II RECEPTOR CALCIUM CHANNEL dicloxacillin ANTAGONISTS COMBINATIONS BLOCKER ANTILIPEMIC SELECTIVE SEROTONIN penicillin VK AGONISTS ATACAND2 ATACAND HCT COMBINATIONS TETRACYCLINES IMITREX AVAPRO AVALIDE CADUET doxycycline hyclate MAXALT COZAAR HYZAAR DIGITALIS GLYCOSIDES minocycline ZOMIG ANTILIPEMICS digoxin MISCELLANEOUS ANTILIPEMIC COMBINATIONS DIURETICS MULTIPLE SCLEROSIS AGENTS metronidazole COPAXONE VYTORIN furosemide sulfamethoxazole-trimethoprim REBIF BILE ACID RESINS hydrochlorothiazide ANTIFUNGALS cholestyramine metolazone ENDOCRINE & METABOLIC fluconazole WELCHOL ANDROGENS itraconazole CHOLESTEROL ABSORPTION torsemide ANDROGEL LAMISIL TABLET INHIBITORS triamterene-hydrochlorothiazide ANTIDIABETICS ZETIA ANTIVIRALS BIGUANIDES HERPES AGENTS FIBRATES CENTRAL NERVOUS metformin acyclovir fenofibrate SYSTEM metformin ext-rel TRICOR VALTREX Your specific prescription benefit plan design may not cover certain categories, regardless of their appearance in this document. Effective January 1, 2007 and sumycin.
Whereas gender analysis has been essential for project design in both Zambia and Ghana the role of women are very different in the two countries. Generally the gender division of labor has been stronger in Ghana than in Zambia. This has had an effect on the position of female traditional healers as well as their ability to participate in project activities. Some of the sociocultural differences are analyzed here. In Zambia, traditional healers have received donor help to be organized on a national basis, and 60 percent of the registered traditional healers are women. The number of women healers is even said to be growing in response to the increasing number of AIDS patients. People call HIV AIDS "Kalaye noko, " meaning "go and say goodbye to your mother, " because most people die in their villages in their mothers' homes. Although women in Ghana are also the ones to care for the ill, the contrast is striking when it comes to practicing healing. In Ghana, there is no functional national traditional healers' association, and the three northern regions have less than one fifth of the estimated healers' registered. Of these few ; registered members, less than 10 percent are women except for one minor sub-region where an active healer has managed to raise the figure to 49 percent. However, the low figure in Ghana is more a reflection of local beliefs than of the actual number of women healers. Also, the Bank-assisted initiative might have unintentionally cemented already existing gender bias by, for example, only training the registered healers, who are overwhelmingly male. According to one female healer in Ghana, women, if they openly practice traditional medicine "are termed witches and every misfortune is blamed on them; in most cases these women are disowned and sent out of their societies. For this reason it is only the queen of witches who is known to heal, because she is so powerful that it is impossible for any member of the society to challenge her." In both countries it was extremely rare to find traditional healers who cultivated medicinal plants, and when it did happen, it was almost exclusively funded by donors. In Zambia, women healers often referred to a spirit guiding them to the medicinal plants, which they collected and prepared for medicine themselves. In Ghana, there was substantial gender bias related to the collection of plants, preparation of medicine, and even to sexuality, which had a positive influence on males but a negative influence on women. Fewer female healers in Ghana were married than were male healers, which one female healer explained by saying that she would not be able to heal if her husband was living with her. Neither would healers, who used traditional African religious rituals in the healing process, send their daughters into the bush to get the plants, because "people would think they were witches." And husbands would not let their wives help to make the medicine "because the medicine would not work" if prepared by a woman. An obvious rationale for this taboo was patrilineal location and succession which meant that a woman at marriage would move to her husband's house, and the family's secret knowledge on plants and its medical use, would thereby be in danger of being uncovered by another family. Healers in Ghana were also reluctant to teach their daughters traditional medicine, but little girls also have eyes and ears, and many women practice medicine, although not openly. That obviously had a negative influence on women's options for income generation through their practice. Only traditional birth attendants TBA ; were almost exclusively women, and most TBAs received some remuneration for their services. But most traditional healers earn their main income from farming and remuneration for healing was in farm products. In Zambia, the declining economy had forced many healers to give up payment in kind, and healers had increasingly turned to their individual ; standard payments for each disease. The highest price was always a cure for infertility, which had to be paid at the arrival of an infant son. The strong division of labor in Ghana gives a unique opportunity through the project to support women and families in HIV AIDS prevention and poverty reduction, thereby enhancing the prospects of success for the project as a whole. The longterm goal of biodiversity conservation could seem abstract to communities suffering from food shortages and hunger; however, short-term income generation through the cultivation and selling of medicinal plants and vegetables leading to improvements in, particularly, children's health could have a catalytic effect on the success of the project. Traditional healers, both male and female, expressed an eagerness to be trained to improve their practice. In Ghana, the mass communication program on HIV AIDS had succeeded in disseminating information on transmission of the disease from one person to another via blood, sexual intercourse, infected needles, and so forth. But communities' knowledge on how it is transmitted was not always complete or accurate. Some communities referred to the danger of eating or bathing together with an AIDS infected person; even shaking hands or using the same clothes was mentioned as a possible way to be infected. None of the communities admitted that there were any affected. 901 8 Street Canmore, AB Maximum Healthcare and 4724 14 Street NE Mobility Limited Calgary, AB Medigas 1535 19 Street NW Calgary, AB Pindrop Your Hearing Centre 845 1 Avenue NE Calgary, AB Shoppers Drug Mart #2332 933 Railway Avenue Canmore, AB Shoppers Drug Mart #2332 933 Railway Avenue Canmore, AB The Hearing Loss Clinic Inc. 161, 31 Southridge Drive Okotoks, AB Medicine Shoppe Pharmacy 3805 Ross Street #251 Red Deer, AB Olds Value Drug Mart 5106 50 Avenue Olds, AB Shoppers Drug Mart #2321 5106 50 Avenue Olds, AB. How lamisil worksOrder lamisil cheapLamisjl, lam8sil, lamiil, lamsil, almisil, lamisi, lamisill, lam9sil, lamisll, lamiisl, lamjsil, pamisil, lamisip, lmisil, lwmisil, lamiskl, lamisli, lamis8l, amisil, lamisik, lsmisil, lamisio, laamisil, lamisiil, lamieil, laimsil, lamissil.Lamisil defense powderLamisil tab 250 mg, serious side effects lamisil, lamisil lotrimin, how lamisil works and order lamisil cheap. Lamisil defense powder, free lamisil coupon, india pharmacy lamisil and doctor effects lamisil side or oral lamisil ringworm. Free lamisil couponLipitor and diabetes, d-dimer false negative, hyperpigmentation definition, douching effects and efferent innervation. Rehab 98, dopamine levels, la montagne guest lodge \u0026 conference centre and epiglottis abnormalities or endocrinology houston.
Copyright © 2009 by Hulk.luservice.com Inc.
|
